WTAP, whose role in leukemogenesis is unknown, might provide an alternate means of modulating the WT1 pathway in AML. We performed a series of experiments to test this possibility. First, we examined WTAP expression in several primary AML samples observing increased levels of WTAP in AML compared with normal peripheral blood mononuclear cells ( Figure 1a ) as well as in AML cell lines (data not shown). Next, the WTAP expression levels were determined in 511 newly diagnosed AML patients using the reverse-phase protein array (RPPA) technique. In comparison with normal bone marrow CD34 þ cells, WTAP expression in bulk AML cells was above normal levels in 32% of patients ( Figure 1b) . Although WTAP levels were not associated with individual cytogenetic abnormalities, some specific molecular mutations such as NPM1 and FLT3-ITD were found to have significant correlation (Pp0.05) with WTAP expression (Supplementary Figure 1A) . In addition, RPPA analysis showed that WTAP levels were positively correlated (R4|0.2|) with levels of various cell proliferation-related proteins (cyclins and Hsp90), antiapoptotic proteins (Bcl-2 and Bax), oncoproteins (FLI1) and proteins important for stem cell functions such as Myc and Ash2L (Supplementary Figure 1B) . To assess the functional significance of increased WTAP expression, its expression was silenced in K562 and HL-60 cells, leading to a significant reduction (Pp0.05) in proliferation (Figure 1c) , and clonogenic survival (Pp0.01) (Figure 1d ). Similar effects on proliferation were observed in the AML cell line OCI-AML3 and in primary AML cells (Supplementary Figure 1C) , suggesting a pro-proliferative role for WTAP in AML.
WTAP knockdown alone did not induce apoptosis but markedly increased (Pp0.01) the extent of apoptosis following etoposide treatment (Figure 1e ). These results provide evidence for an association between the increased expression of WTAP and chemoresistance in AML.
To examine the role of WTAP in AML progression in vivo, we performed tumor xenograft experiments in nude mice. As shown in Figure 1f , the growth rates and masses of tumors derived from WTAP-knockdown cells were significantly reduced (Pp0.01) compared with control. To complement this analysis, the in vitro transforming activity of WTAP was examined by investigating its effects on growth of the Ba/F3 cell line. This line depends on interleukin 3 (IL-3) for survival and proliferation, but this dependence can be released by the transgenic expression of suitable oncogenes. 9 Whereas control Ba/F3 cells were not viable in the absence of IL-3 at 72 h, WTAP-expressing Ba/F3 cells were able to maintain growth factor-independent proliferation, as demonstrated by significantly higher (Pp0.01) number of viable cells (Figure 1g ), suggesting that WTAP harbors oncogenic activity.
The aberrant cellular proliferation and terminal differentiation block of myeloid cells are two hallmarks of AML. 10 Having shown that WTAP regulates growth and survival, we investigated whether WTAP has a role in myeloid cell differentiation. As shown in Figure 1h , knockdown of WTAP promoted phorbol 12-myristate 13-acetate (PMA)-induced myeloid differentiation, as revealed by an increase in the expression of myeloid differentiation markers CD11b and CD14 compared with control cells. These results S-methionine-labeled fulllength WTAP was incubated with GST or GST-Hsp90 protein immobilized on glutathione-sepharose beads, and bound WTAP was detected by fluorography. Twenty percent of the in vitro-translated protein was used for pull-downs. (c) K562, MV4-11 and Kasumi-1 leukemia cells were treated with the Hsp90 inhibitor ganetespib (1 mM) for 24 h and analyzed for WTAP expression by western blotting. (d) AML blasts were isolated from peripheral blood or bone marrow of AML patients using Ficoll gradient separation followed by treatment with ganetespib (1 mM) for 24 h; WTAP expression was analyzed by western blotting. (e) MV4-11 tumor-bearing animals were given single doses of vehicle and ganetespib as described previously, 14 and after 6 h, tumors were removed for western blot analysis using WTAP and b-actin antibody. (f ) K562 cells were treated with vehicle ( À ) or proteasomal inhibitor (bortezomib; 100 nM) for 2 h and then treated with additional vehicle or ganetespib (1 mM) for 24 h, and cell lysates were subjected to western blot analysis using anti-WTAP and anti-b-actin antibodies. (g) K562 cells were treated as above for 6 h, and proteins extracts were immunoprecipitated (IP) with anti-WTAP followed by immunoblotting with antiubiquitin (top panel) and anti-WTAP (bottom panel) to detect the ubiquitinated WTAP (Ub-WTAP) and WTAP protein levels, respectively.
suggest that increased expression of WTAP in AML not only supports cell proliferation but also induces the differentiation block. Our RPPA analysis suggested a link between WTAP and mammalian target of rapamycin (mTOR) expression; and given that the mTOR pathway is deregulated in a number of cancers including AML, 11 we hypothesized a putative regulatory role of WTAP on mTOR activity in AML. As shown in Figure 1i , WTAP knockdown induced a decrease in the phosphorylation levels of mTOR and its downstream effector p70 ribosomal subunit 6 kinase (pS6K) compared with control shRNA.
To further understand the participation of WTAP in leukemogenesis, we performed transcriptomic analysis with RNA-Seq on WTAP knockdown in K562 cells. Gene ontology analysis indicated that cell adhesion and regulation of cell proliferation are the most enriched functionalities (Supplementary Figure 1D and Supplementary Table 2 ). Among the most relevant genes affected by WTAP with recognized roles in leukemia are CD4, CD44, CEBPA, CSF1R, MPO, ABCG2, TCL1A, CYP1A1, CYP3A4, FGFR1, PTPRC (CD45), CD83, CD86, CD9 and CCR4. Consistent with its described role in RNA processing, we determined that WTAP knockdown affected exon usage of 93 genes, including important factors such as MLL and MSI2. Interestingly, we also observed that WTAP affects the processing of its own transcript, very likely via polyA site selection. Complete analysis can be accessed in GEO (GSE46718-http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token =jbkjjswaqscegjs&acc=GSE46718). Results of RNA-Seq and RPPA were compared and of the 82 genes found in the RPPA analysis, 48 genes (more than 57%) showed a significant change (Po0.001; Fisher's exact test) in their mRNA levels as determined by RNA-Seq.
Mutations of WTAP were not observed in the TCGA analysis of AML.
12 Therefore, the etiology of increased WTAP expression in AML remains unexplained. We next sought to determine the potential mechanism that may contribute to an increase in WTAP expression in AML. The molecular chaperone Hsp90 maintains the stability of many tumor-promoting oncoproteins, 13 including WT1.
14 Keeping in mind the connection between WT1 and WTAP, we investigated the potential interaction between Hsp90 and WTAP. First, we determined that WTAP co-immunoprecipitates with Hsp90 (Figure 2a ), whereas treatment with the Hsp90 inhibitor ganetespib significantly reduced the binding of Hsp90 to WTAP. Therefore, formation of the WTAPHsp90 complex is dependent on the chaperoning activity of Hsp90. Studies have shown that Hsp90 client proteins shift the primary chaperone association from Hsp90 to Hsp70 following inhibition of Hsp90 activity. 15 Accordingly, our results showed that ganetespib treatment increased WTAP association with Hsp70 ( Figure 2a) . Furthermore, the GST pull-down assay showed a direct interaction between WTAP and Hsp90 (Figure 2b) . To understand the functional significance of the association of Hsp90 with WTAP, we investigated the effects of Hsp90 inhibitors on WTAP protein stability. Ganetespib treatment promoted the degradation of WTAP in K562 (CML), MV4-11 (AML) and Kasumi-1 (AML) cell lines, previously shown to be highly sensitive to ganetespib (Figure 2c) . 16 Marked reduction in WTAP expression was similarly observed in blasts exposed to ganetespib (Figure 2d) . Furthermore, ganetespib inhibited AML tumor growth in nude mice, as we reported previously, 14 and WTAP expression in xenograft tumors (Figure 2e ). Inhibition of Hsp90 induces polyubiquitination and proteasomal degradation of Hsp90 client proteins. 17 We confirmed that pretreatment with proteasomal inhibitor bortezomib largely prevented ganetespib-induced degradation of WTAP (Figure 2f) , and higher levels of ubiquitinated WTAP were observed in the presence of the combination of bortezomib and ganetespib compared with either agent alone (Figure 2g) . Together, these data show that ganetespib-mediated degradation of WTAP is dependent on the ubiquitin-proteasome pathway, very similar to other bonafide Hsp90 client proteins.
In summary, our study shows that WTAP has an important role in abnormal proliferation and arrested differentiation of leukemia cells, and WTAP is a novel client protein of Hsp90. Therefore, WTAP may be a promising novel therapeutic target in AML. Further investigation aimed to elucidate the mechanism of action of WTAP is warranted.
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